母体循环中与胎儿生长受限相关的血液生物标志物
本文综述了用于预测胎儿生长受限(FGR)的分子生物标志物(蛋白质、代谢物或核糖核酸)的研究进展。目前多数研究采用病例对照设计且未在独立队列中验证;作者提出需要大规模前瞻性研究及预设验证方案,并指出在90%特异度下灵敏度≥60%的筛查试验可能具有临床价值。
要点
- FGR与死产风险增加三至四倍相关,识别小于胎龄儿(SGA)并实施胎儿监测和适时分娩可降低死产风险。
- 临床现有方法识别SGA胎儿灵敏度低:约80%病例未被检出,宫高测量仅检出20%,普遍孕晚期超声最多检出57%。
- 作者认为在90%特异度下灵敏度≥60%的筛查试验可能具有临床价值,或可降低死产。
核心结论
- 需要大规模前瞻性研究并预设验证方案和队列,以开发稳健的FGR检测方法。
- 作者认为在90%特异度下灵敏度≥60%的筛查试验若得以开发,可能具有临床价值,并可能降低死产。
研究设计与样本
- 综述总结了识别可用于更好预测FGR的分子生物标志物(蛋白质、代谢物或核糖核酸)的相关研究。
主要发现
- FGR与死产风险增加三至四倍相关。
- 约80%的SGA病例未被检出。
- 宫高测量仅检出20%的SGA胎儿。
- 普遍孕晚期超声最多检出57%的SGA胎儿。
- 多数研究采用病例对照设计,未在独立队列中进行验证。
关键数值与推荐
- SGA定义为估计胎儿体重和/或腹围小于第10百分位。
- 在90%特异度下灵敏度≥60%的筛查试验可能具有临床价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数研究采用病例对照设计,未在独立队列中进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fetal growth restriction (FGR) is associated with threefold to fourfold increased risk of stillbirth. Identifying FGR, through its commonly used surrogate-the small-for-gestational-age (SGA, estimated fetal weight and/or abdominal circumference <10th centile) fetus-and instituting fetal surveillance and timely delivery decrease stillbirth risk. Methods available to clinicians for antenatal identification of SGA fetuses have surprisingly poor sensitivity. About 80% of cases remain undetected. Measuring the symphysis-fundal height detects only 20% of SGA fetuses, and even universal third trimester ultrasound detects, at best, 57% of those born SGA. There is an urgent need to find better ways to identify this at-risk cohort. This review summarises efforts to identify molecular biomarkers (proteins, metabolites, or ribonucleic acids) that could be used to better predict FGR. Most studies examining potential biomarkers to date have utilised case-control study designs without proceeding to validation in independent cohorts. To develop a robust test for FGR, large prospective studies are required with a priori validation plans and cohorts. Given that current clinical care detects 20% of SGA fetuses, even a screening test with ≥60% sensitivity at 90% specificity could be clinically useful, if developed. This may be an achievable aspiration. If discovered, such a test may decrease stillbirth.
引用
- Tong S, Joy Kaitu'u-Lino T, Walker SP, et al. Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. Prenat Diagn. 2019. PMID: 31299098. doi:10.1002/pd.5525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。